Prevalence and eradication rate of helicobacter pylori infection among the patient using the low dose of aspirin attending outpatient clinic at tertiary hospitals in Dodoma, Tanzania. A prospective longitudinal observational study

Prevalence and eradication rate of helicobacter pylori infection among the patient using the low dose of aspirin attending outpatient clinic at tertiary hospitals in Dodoma, Tanzania. A prospective longitudinal observational study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Prevalence and eradication rate of helicobacter pylori infection among the patient using the low dose of aspirin attending outpatient clinic at tertiary hospitals in Dodoma, Tanzania. A prospective longitudinal observational study Lawi John, Emmanuel Sindato, Baraka Alphonce This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4950972/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction: Low-dose of aspirin has been widely used by health providers as primary prevention of major cardiovascular events, its benefit counterbalanced by side effects The synergistic interaction between H. pylori infection and LDA use has been identified as a significant risk factor for peptic ulcer disease, chronic gastritis, perforation, bleeding and gastric cancer with increase folds two to three times among H . pylori positive patient. Methodology: A prospective observational longitudinal study was carried out for patients using the low dose of aspirin attended outpatient clinic at Benjamin Mkapa Hospital and Dodoma Regional Referral Hospital in between September, 2023 to April, 2024.A sample size of 159 participants were recruited, aged 18 years or older met specified inclusion criteria. At baseline Demographic data, clinical characteristics were extracted from questionnaire form. Blood sample was collected for full blood picture and stool for H. pylori antigen test. Data analysis employing frequencies, chi-square test and binary logistic regression was done by using SPSS version 26. Statistical significance was ruled out for p < 0.05. Results Among 159 patients enrolled in this study, mean age was 57 (IQR 20–75), 57.7% were female. The prevalence was 74.8%. Variables which show significance in this study include use of alcohol [p value = 0.007, OR = 3.24, 95% CI (1.38–7.61)], non-adherence of medications [p value = 0.001, OR = 5.5, 95% CI (2.11–14.46)], smoking [p value < 0.001, OR = 13.61, 95% CI (2.30–56.30)]. Conclusion H . pylori infection is frequently observed in patients using low dose of aspirin attending medical clinic to tertiary hospital in Dodoma. Factors which have significance with helicobacter pylori eradication failure were smoking, alcohol and non-adherence to medication during treatment period. Helicobacter pylori infection low dose of aspirin eradication rate risk factors Figures Figure 1 Figure 2 Figure 3 Background Globally it is estimated that about one billion people are taking a low-dose aspirin(LDA) for both primary prevention and secondary prevention of cardiovascular events( 1 ). The use of low dose aspirin use varies widely across regions with different income groups with lower usage in low- and lower-middle-income countries accounting for 0.6% and 1.2% respectively. The prevalence is much higher in upper-middle-income countries at 11.7% and 17.7% in high-income countries ( 2 ). In United states of America (USA) over 30% of adult population are using LDA for primary and secondary prevention of cardiovascular events, however the trend decreased from 32% in 2012 to 30% in 2015 ( 3 ). However, the trend of using low dose aspirin is reported to raise significantly in low-income countries because of increased prevalence of cardiovascular disease ( 4 , 5 ). High prevalence reaching up to 47.2% was reported in sub-Saharan countries ( 6 ). Helicobacter pylori infection is very prevalent among patients using low dose aspirin reaching up to 89.8% compared to 68.7% among non-users (Sostres & Lanas, 2018). This higher H. pylori infection in patients using LDA compared to non-users is a primary result of LDA effect on cyclooxygenase enzymes causing decreased protective prostaglandins in the gastric mucosa ( 7 , 8 ). This weakened mucosal barrier together with increased gastric acidity due to aspirin creates a favorable environment for H. pylori colonization and persistence among these patients ( 9 , 10 ). Damage of gastric mucosal can be caused even with very low doses of aspirin (10 mg daily) because it is known to reduce the levels of gastric mucosal prostaglandins ( 11 – 14 ). Several other risk factors for H. pylori infection in LDA users which are shared with non-users. Such factors include advanced age, concurrent use of corticosteroids or NSAIDs, smoking, alcohol consumption, poor dietary habits, and poor hygiene ( 15 – 17 ). These factors tend to compound the mucosal damage resulted from LDA, making the stomach even more susceptible to H. pylori colonization and persistence ( 1 ). H. pylori eradication is potentially significant for preventing complications among LDA users ( 10 ). It is necessary to eradicate H. pylori infection because of its complications including peptic ulcers, gastric cancer, and MALT lymphoma due to chronic inflammation of the stomach lining ( 18 – 20 ). The test and treat for H. pylori strategy is reported to be mandatory among patients using LDA especially in settings with high prevalence of H. pylori ( 1 ). The eradication rate of H. pylori infection is termed significant when reaches 90% successful as recommended by WHO ( 21 ). the eradication rate of H pylori is still low especially in developing countries where the prevalence is verry high. In Africa the pooled eradication rate was 79% being high in Ethiopia (90%) and lower in East Africa zone including Tanzania (69%) and Kenya (68%), and lowest in Ivory Coast (22.3%) ( 22 ). Studies have shown the eradication failure to be higher among LDA users. This is explained mainly by mucosal damage caused by aspirin which creates conducive environment of H. pylori to persist ( 10 , 23 ). Also, Aspirin tend to inhibit cyclooxygenase-1 (COX-1) resulting in raised acid production in the stomach hence reducing the effectiveness of some antibiotics like clarithromycin and Amoxicillin ( 24 – 26 ). Other factors associated with eradication failure includes alcohol consumption, smoking, poor adherence to medication, bacterial resistance, and dosage and timing of dosage ( 27 – 30 ). Understanding the prevalence and eradication rate of H. pylori among LDA patient population is crucial, as it may shed light on the potential implications of H. pylori infection on gastrointestinal complications and its association with low dose aspirin use ( 14 , 31 ). This study aimed to determine prevalence, eradication rate and risk factors for eradication failure of H. pylori among patients using LDA attending outpatient clinics at public tertiary hospitals in Dodoma, Tanzania. Methodology Study design Prospective longitudinal observational study Study settings This study was conducted at two hospitals which are Dodoma regional referral and Benjamin Mkapa hospitals. Dodoma is the capital city of Tanzania with rapidly growing population of 3,085,625 as per national data of 2022 (NBS, 2022). Both hospitals serve as consultancy, diagnostic and teaching hospital of the University of Dodoma. The hospitals offer a wide range of medical specialties including Internal medicine and have equipped laboratories with modern equipment for diagnosis. Benjamin Mkapa hospital and Dodoma regional referral hospital has a bed capacity of 400 and 420 respectively. These hospitals have specialized outpatient clinic of average of aspirin users of 1800 and 2160 at DRRH and BMH respectively per year. Study duration Study was conducted for eight ( 8 ) months from September, 2023 to April, 2024. Study population The study enrolled adult patients aged 18 years above who are using LDA attending outpatient clinic at department of internal medicine at Dodoma regional referral hospital and Benjamin Mkapa hospital during the study period Inclusion criteria The study included adult patients aged 18 years and above using low dose of aspirin > 3 months as prophylaxis for MACE, patients voluntarily signed the consent form to participate in the study. Exclusion Criteria All patients who were using antibiotics within 30 days All patients who reported to be allergic to the regimen used in this study All patients who were on (PPI, NSAIDS, Macrolides, Bismuth, Steroid, Penicillin sampling technique Simple random technique was used to enroll all study participants who met inclusion criteria giving equal chance of participate in this study. Until the sample size was reached. Sample size estimation The formula (Krejcie &Morgan) was used to calculate sample size as follows: $$\:\text{s}=\frac{{x}^{2}*N*p\left(1-p\right)}{{d}^{2}\left(N-1\right)+\:{\text{x}}^{2}p\left(1-p\right)}$$ $$\:\text{s}=\frac{3.841*3960*0.085\left(1-0.085\right)}{{0.05}^{2}\left(3960-1\right)+\:3.841\text{*}0.085\left(1-0.085\right)}$$ $$\:\text{s}=\frac{1182.9857}{10.1627}=116.4046\:\approx\:116\:\text{L}\text{D}\text{A}\:\text{u}\text{s}\text{e}\text{r}\text{s}.$$ Where : \(\:p\) = the expected population proportional based on previous studies: 8.5%( 6 ) \(\:{x}^{2}\) = the value of chi-square for 1 degree of freedom at 95% confidence level: 3.841. \(\:\:\:\:d\) = the degree of accuracy expressed as a proportion: 5% \(\:\:\:\:N\) = the estimated population size of LDA patients served at BMH (1800) and DRRH (2160) per year. (according to BMH and DRRH routine report, 2022). \(\:s\) = required sample size Therefore, a minimum sample size for this study with an attrition rate of 30% of the sample size calculated was 151 LDA users which were proportionally distributed based on the number of LDA users served annually at BMH and DRRH which is 69 (45.45%) and 82 (54.55%) respectively. Data collection tools, methods and Procedure Data collection tools and methods Data were collected for the specified period of time by means of face-to-face interview using a structured questionnaire. Data collection was carried out by researcher and research assistant who asked questions to the study participants and explained the meaning of the question so as to ensure uniformity of data. A questionnaire included socio-demographic information, medication use, and factors associated with H. pylori eradication rates. Study procedure All patients using LDA who met inclusion criteria of the study were told the aim, safety and benefits of the study and were requested to sign a written informed consent form. For those who were un able to read and write, researcher or research assistants read for them and they signed form by using thumb sign. History taking, general examination and laboratory investigation commenced after they consent to participate in this study. Prevalence of H. pylori was established by using Stool antigen test as explained below and for those with positive test were then managed by using triple therapy as per STG and then followed up until eighth week post commencement of medication and be tested for H. pylori. All patients with SAT positive at 8 weeks were declared eradication therapy failure, and those with negative SAT were declared eradication therapy success. During follow up phone number of the patients and close relative was used to reach the patients and remind them to come back continuation of treatment regimen and adherence assessment score using MMAS4 and for the stool antigen test. For the patients who did not bring stool sample and those who were not reachable in three consecutive days were considered lost to follow-up. However, in this study there were no lost to follow-up recorded making a response rate of 100% among study participants. Laboratory procedure and data collection Stool Antigen Testing (SAT) this non-invasive diagnostic method was used for establishing prevalence of H. pylori and assessing eradication rate because it has sensitivity of 95–100% and specificity of 90%. The test was done first day of enrollment and at eight weeks from day one of treatment for assessing eradication rate. The patient was instructed to collect a small stool sample in a clean, dry, sealable container which was provided at hospital. They were instructed to avoid contamination with urine, water, or toilet paper to ensure clean samples. Stool collection tube must be sterile with built in spoon for collection of specimens, clean dry bed pan or a piece of dry plastic or piece of hard paper Don’t urinate on specimen tube container or mix the specimen with water The container was labeled with patients’ hospital identification number and was sent to laboratory immediately so as can be processed within 72 hours. The stool sample were then tested by immunochromatography assay (H. PYLORI QIUCK CHECK™ then laboratory technician assigned for this study and interpretation was sent to researcher for recording. Full blood count this was done mainly to assess the hematological parameters with the interest of assessing hemoglobin level and platelets. Blood samples were collected by experienced nurses and doctors who were available at the post during the study period by following all sterile guideline. The EDTA tube with sample was labelled with identification number of the patient and promptly sent to laboratory. The machines. The calibrated XN 2000 SYMEX machine. Made in India. The result was then interpreted by the qualified laboratory technician and then recorded by the researcher. Definition of variables Independent variables Included demographic data and clinical characteristics which are, age, gender, place of residence, education level, body mass index. Blood pressure and indication of using low dose of aspirin. Factors associated with H. pylori eradication rates including diagnosed HPI, treatment adherence to medication, medication regimen, symptoms duration, alcoholism, smocking, and chronic medical condition. Dependent variable was eradication of pylori infection at eighth week post commencement of medication. It was categorized into two groups which were eradication success and eradication failure when test was negative and positive respectively. Validity and reliability Study validity Before gathering data, a comprehensive process was undertaken to ensure the questionnaire validity. Initially, pilot study was done at DRRH including 15 patients to assess the questionnaire's consistency and any potential issues were identified and corrected with aid from supervisors. Additionally, to maintain the quality of data collection, the research assistants were provided with comprehensive training and orientation by the principal researcher. This training equipped them with the necessary skills and knowledge to proficiently carry out their duties and responsibilities in the research process, ensuring the validity of the data collected for the study Reliability All laboratory procedures were conducted by the experienced laboratory technicians designated for the study under the standard guideline adapted by both hospitals. Also, all blood sample were collected by well experienced doctors and nurses by following the standard protocols. Data analysis Data was analyzed by using IBM SPSS version 26. Descriptive statistics were used to summarize demographic and clinical characteristics. All categorical variables were analyzed as frequency and percentages whereas continuous variables were analyzed as mean with standard deviation or medians with interquartile ranges according to distribution of data. Inferential statistics included the use of Pearson’s chi-square test and binary logistic regression to assess association between independent and dependent variables. This was done to assess factors associated with eradication rate of H. pylori in such a way that; all variables with p value less than 0.2 in chi square test were taken into univariate regression where crude odds ratio was established. All variables with p value < 0.05 was then subjected into multivariable regression where adjusted odds ratio was established after controlling cofounders. 95% confidence interval was calculated and a p value < 0.05 were considered statistically significant. Ethical consideration Ethical approval was obtained from the University of Dodoma’s IRREC with reference letter number MA.84/261/02/A/66/9. Letter was submitted to hospital directors of BMH and DRRH for data collection permit. Permit was released from both health facility and data collection exercise effectively started from October 2023. Stringent measures were implemented to safeguard the confidentiality of participants and protect their sensitive information throughout the study. To maintain anonymity, participants were assigned unique identification numbers rather than using their real names. All study-related documents, both hard copies and electronic files, were stored in a highly secure location, accessible only to authorized personnel, including the principal investigator and research assistants. Electronic data were further fortified through the use of robust password protection. The utmost care was taken to ensure that all information collected from participants remained strictly confidential. The participants were informed that they had a chance to withdraw from the study at any stage of the study, and were given an equal care with those who have remained in the study. Participants tested positive kept on regimen of Triple therapy for 2 weeks then follow up after 8 weeks those still tested positive declared as eradication failure and referred on second line regime as per protocol suggested HDDT or Bismuth quadruple therapy. Close follow up are done for eradication of helicobacter pylori infection. Results Study participant enrolment flow Chart Socio-Demographic and Clinical Characteristics of Study Participants The total number of patients using low dose of aspirin attended from both tertiary hospitals were 1321 in which 981 were excluded due to antibiotic use. 341 patients met inclusion criteria in which 181 patients were excluded due to sampling technique. Therefore, total number of participants enrolled in this study were 159, with median age of study participants was 59 years (IQR 20–75 years) majority were aged 60 years and above 75(49.7%) followed by 40–59 years (48.31.8%). Female gender was the most encountered among these patients accounting 87(57.7%), regarding education level majority accounting 56(37.1%) had secondary education followed by college level (Table.1). Majority of study participants had elevated blood pressure, about 48(31.8%) were using alcohol, total of 34 (22.5%) were smoking whereby 19(55.9%) were smoking less than 20 packs per year and 15(44.1%) were smoking more than 20 packs per year. Significant number of these patients had anemia with Hemoglobin less than 11.5g/dl, they were about 31(20.5%) (Table 4.1). Regarding medical history of patients using low dose aspirin, majority were under this medication for more than 12 months followed by 7–12 months accounting 60(39.7) and 50(33.1%) respectively. The most common medical condition which was the reason of using low dose aspirin were ischemic heart disease 50(33.3%), myocardial infarction 32(21.2%) and stroke 24(15.9%) (Table 4.2). Table 1 Socio-demographics and clinical characteristics of patients using low dose aspirin (N = 151) Variables Frequency (n) Percentage (%) Age 59.0 ± 20 Median (IQR) Age group (years) < 40 28 18.5 40–59 48 31.8 ≥ 60 75 49.7 Sex Male 64 42.4 Female 87 57.6 Education level Non formal 11 7.3 Primary 33 21.9 Secondary 56 37.1 College 51 33.8 Body mass index(kg/m 2 ) Normal (18.5–25) 45 29.8 Over weight (25-29.9) 89 58.9 Obese (≥ 30) 17 11.3 Blood pressure (mm hg) Normal 34 22.5 Elevated 51 33.8 Stage one 46 30.5 Stage two 20 13.2 Alcohol use Yes 48 31.8 No 103 68.2 Smoking Yes 34 22.5 No 117 77.5 Source of water Boiled water 110 72.8 Un boiled water 41 27.2 Hemoglobin level (g/dl) 12 months 60 39.8 Therapy used lansoprazole 20mg + Clarithromycin 500 + Tinidazole 500mg BID 14/7 58 38.4 Rabeprazole 20mg + amoxicillin 1000mg 12hrly for 14/7 55 35.7 Negative Stool for antigen 39 25.9 Indication of LDA Ischemic heart disease 87 57.6 Stroke 37 24.5 Peripheral arterial disease 27 17.9 Prevalence of H. Pylori Infection among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma The prevalence of helicobacter pylori among patients using low dose aspirin was noted to be unacceptably very high reaching 74.8% (Fig. 4.1). Helicobacter pylori was diagnosed by using stool antigen test. Helicobacter Pylori Eradication Rate among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma Total of 81(71.7%) patients using low dose aspirin were tested negative at eight weeks. The eradication rate of H. pylori among patients using low dose Aspirin was as high as 71.7% where ass eradication failure was reaching up to 28.3% (Fig. 4.2). Factors Associated with Eradication Failure of H. Pylori Infection among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma In chi square test several factors were found to be associated with eradication failure of helicobacter pylori. Such factors are Age (p value = 0.037), use of alcohol (p value = 0.006), smoking (p value < 0.001) and self-reported adverse effect of medication (p value < 0.001) (Table 4.3). All variables showing significant association with p value less than 0.05 were taken into univariate regression along with those with p value less than 0.025. Table 3 : Univariate and multivariate regression of factors associated with helicobacter pylori eradication failure Variables H. pylori eradication Univariate regression Multivariable regression Success (%) Failure (%) COR (95% CI) P value AOR (95% CI) P value Age (years) <40 11(50.0) 11(50.0) 3.0(1.07-8.42) 0.037 0.20(0.04-1.03) 0.054 40- 59 28(80.0) 7(20.0) 0.8(0.27-2.09) 0.582 0.24(0.05-1.18) 0.079 ≥60 42(75.0) 14(25.0) Ref Sex Male 31(66.0) 16(34.0) Ref Female 50(75.8) 16(24.2) 1.6(0.71-3.68) 0.256 Body mass index (BMI) Normal (18.5-25) 28(77.8) 8(22.2) Ref Overweight (25-29.9) 46(74.2) 16(25.8) 1.22(0.46-3.21) 0.691 0.55(0.62-1.86) 0.332 Obese (>30) 7(46.7) 8(53.3) 4.0(1.11-14.43) 0.034 5.44(0.85-34.79) 0.074 Alcohol use Yes 21(55.3) 17(44.7) 3.24(1.38-7.61) 0.007 3.70(1.07-12,80) 0.039 No 60(80.0) 15(20.0) Ref Smoking Yes 8(33.3) 16(66.7) 9.13(3.34-24.97) <0.001 8.16(1.31-50.94) 0.025 No 73(82.0) 16(18.0) Ref Non adherence to treatment Yes 10(41.7) 14(58.3) 5.5(2.11-14.46) 0.001 5.6(1.60-19.31) 0.007 No 71(79.8) 18(20.2) Ref In univariate binary regression, several variables were statistically significantly associated with h. pylori eradication failure. Such variables include age below 40 years [p value = 0.037, COR = 3.0, 95% CI (1.07–8.42)], obesity [p value = 0.034, COR = 4.0, 95% CI (1.11–14.43)], use of alcohol [p value = 0.007, COR = 3.24, 95% CI (1.38–7.61)]. Other variables were non adherence of medication due to self-reported adverse effect [p value = 0.001, COR = 5.5, 95% CI (2.11–14.46)], smoking [p value < 0.001, COR = 9.13, 95% CI (3.34–24.97)] (Table 4.4). All variables with p value less than 0.05 in univariate were then taken into multivariate regression to establish adjusted odds ratio. In multivariate regression, it was found that patients with non- adherence to medication were about six-fold at risk of eradication failure compared to their counterpart [p value 0.007, AOR = 5.6, 95% CI (1.6-19.31)]. Also, patients with history of using alcohol were approximately four times at high risk of eradication failure compared to those who do not use alcohol. Furthermore, smoking was significant factor for eradication failure in such a way that patients who are smoking were eight-fold at risk of eradication failure compared to those who do not smoke at all [p value = 0.025, AOR = 8.16, 95% CI (1.31–50.94) (Table 4.4). Table 4 : Univariate and multivariate regression of factors associated with helicobacter pylori eradication failure Variables H. pylori eradication Univariate regression Multivariable regression Success (%) Failure (%) COR (95% CI) P value AOR (95% CI) P value Age (years) <40 11(50.0) 11(50.0) 3.0(1.07-8.42) 0.037 0.20(0.04-1.03) 0.054 40- 59 28(80.0) 7(20.0) 0.8(0.27-2.09) 0.582 0.24(0.05-1.18) 0.079 ≥60 42(75.0) 14(25.0) Ref Sex Male 31(66.0) 16(34.0) Ref Female 50(75.8) 16(24.2) 1.6(0.71-3.68) 0.256 Body mass index (BMI) Normal (18.5-25) 28(77.8) 8(22.2) Ref Overweight (25-29.9) 46(74.2) 16(25.8) 1.22(0.46-3.21) 0.691 0.55(0.62-1.86) 0.332 Obese (>30) 7(46.7) 8(53.3) 4.0(1.11-14.43) 0.034 5.44(0.85-34.79) 0.074 Alcohol use Yes 21(55.3) 17(44.7) 3.24(1.38-7.61) 0.007 3.70(1.07-12,80) 0.039 No 60(80.0) 15(20.0) Ref Smoking Yes 8(33.3) 16(66.7) 9.13(3.34-24.97) <0.001 8.16(1.31-50.94) 0.025 No 73(82.0) 16(18.0) Ref Non adherence to treatment Yes 10(41.7) 14(58.3) 5.5(2.11-14.46) 0.001 5.6(1.60-19.31) 0.007 No 71(79.8) 18(20.2) Ref Discussion The prevalence of helicobacter pylori among patients using low dose aspirin in this study was noted to be very high accounting for 74.8%. The prevalence of H. pylori infection among patients using low dose aspirin is reported to be high in different geographical locations, however many studies reported the prevalence to be very high in developing countries ( 16 , 17 , 32 ). Several other studies have reported that "H. pylori infection is frequently found in LDA users. A systematic review and meta-analysis which involved new studies from different regions including Europe, Japan and Asia reported the increased H. pylori complication among the LDA users ( 33 ). H. pylori prevalence is reported to be 50% of the global population, varying from 20–40% in developed nations and more than 80% in certain developing countries which is very similar to this study. However, the study done in UK was contrary to other studies in same developed countries and was similar to our study with very high prevalence reaching up to 89.8% among LDA users and 68.7% among non-users. ( 23 ). However, this systematic review was different from a reported randomized trial which included studies done in United Kingdom (UK), Wales and Northern Ireland where the prevalence 17% ( 34 ). However, in this study serological test was used to establish the prevalence which was different from other study which used SAT. The study findings in this region shows that the low prevalence and eradication rate was observed to be higher than in places with high prevalence. Among low dose aspirin users. Furthermore the study reported that in the pilot study the prevalence found to be 23% with eradication success of 91.3%.eradication success was confirmed by using breath test ( 34 ). Some cohort studies conducted in Korea have reported the composite prevalence of H. pylori among patients using Low dose aspirin presenting with Upper Gastrointestinal Bleeding (UGIB) to be 64.2%. The research revealed that among the individuals examined, 57.9% in the study group and 51.8% in the control group were identified as having H. pylori infection. The diagnostic test used was Urease test which is different from our study ( 31 , 35 , 36 ). The prevalence of H. pylori among LDA users can be explained based on various facts. Such facts include the direct mucosal damage caused by aspirin which expose the gastric mucosal leading to invasion of H pylori. Low-dose aspirin inhibit cyclooxygenase (COX) enzymes which reduce the protective prostaglandins hence increasing the vulnerability to H. pylori invasion. Some studies reported the synergism oh H. pylori and LDA in such a way that H. pylori tend to induces chronic inflammation in the gastric mucosa and adheres to damaged area which exacerbating the mucosal damage caused by Aspirin ( 10 , 36 – 38 ). Helicobacter Pylori Eradication Rate among Low Dose Aspirin Users In this study eradication of H. pylori was assessed by using the stool antigen test (SAT) at eighth week post treatment commencement. This non-invasive diagnostic test is well reliable because it has high sensitivity ranging from 90–95% and specificity ranging from 95–98%, meaning that the test has a high accuracy in correctly identifying those with and without the infection respectively ( 39 , 40 ). In this study the eradication success of H. pylori was 71.7% among patients using low dose aspirin at eight weeks. The eradication failure of H. pylori was reaching up to 28.3%. According to Khadim et al. (2024) and other scholars the effectiveness of H. pylori eradication is classified as excellent if the success rate is 95% or higher, good if it is 90% or higher, borderline acceptable if it falls between 85% and 89%, and unacceptable if it is below 85% ( 27 ). The eradication rate observed in this study was under the category of unacceptable eradication success which accounted for 71.7%. Similar to this study, several studies have reported H. pylori eradication success rates below 90% which is recommended by WHO. A systematic analysis of 22 studies in Africa have revealed a pooled eradication rate of 79%. This systematic analysis reported significant variability, with higher success rate in Ethiopia (90%), Nigeria (87%), South Africa (86%), Egypt (82%), and Morocco (82%). However, lower rates were reported most in East Africa zone including in Tanzania (69%) and Kenya (68%), while the lowest being in Ivory Coast (22.3%) ( 22 ). This lower rate were also observed in Chile where eradication rate was reported to be 38% ( 41 ). The challenge of eradicating H. Pylori is higher even in some developed countries including Spain where it was reported to be 71.1% which is lower than the recommended by WHO ( 42 ). The observed lower eradication rates of H. pylori infection may be explained by several factors varying from antibiotic resistance where H. pylori strains can be resistant to key medication like clarithromycin and metronidazole and amoxicillin. Some studies have reported the resistance reaching up to 90% to metronidazole which is used in many of the eradication therapy in Africa including Tanzania ( 16 , 17 , 32 , 43 ). Also, inadequate treatment regimens which is explained by suboptimal dosages and treatment duration ( 44 ) poor patient adherence to medication, and poor healthcare system are significant challenges mainly in developing countries ( 45 – 47 ). Eradication success of H. pylori is very low and vary with region being higher in sub-Saharan Africa including the east Africa zone. This variability may be suggestive of resistivity of bacteria due to several factors including over the counter drugs which exposes patients to antibiotic resistance. Regarding that the sensitivity test for H. pylori is costly and hard to be managed by each hospital, the regional test may be useful in establishing the effective regimen so as to raise the eradication rate of H. pylori among patients. Predictors of Eradication failure of H. pylori This study has found significant predictors of H. pylori eradication failure include the use of alcohol, smoking, and self-reported adverse effect of medication. Similar findings were reported from other studies including that of China which showed that excessive alcohol consumption and smoking were independent predictors of H. pylori eradication failure ( 29 , 30 , 48 ), however another study done in China have reported association between alcohol and smoking with eradication failure in > 7 days regimen but no significant association when vonoprazan (VPZ)-based therapy regimen was given ( 49 ). The difference in regimen may be the great influence on eradication failure as studies have shown H. pylori have developed resistance to most of used antibiotics. However, there may also be some effect of alcohol on non VPZ based regime. Alcohol consumption can negatively impact the eradication of H. pylori by several mechanisms. Alcohol may cause direct irritation and inflammation of the gastric mucosa which hinder the healing process and reduce the effectiveness of antibiotic therapy ( 48 ).Furthermore, alcohol tend to interfere with the metabolism and absorption of the medications used to eradicate H. pylori hence reducing their concentration in the stomach which lead to eradication failure ( 21 , 29 , 30 , 50 ). Smoking is a significant factor for eradication failure, this may be because smoking cause detrimental effects on gastric health and H. pylori eradication. Smoking reduces gastric blood flow, which can impair the delivery of antibiotics to the stomach lining ( 18 , 29 ). Also, smoking stimulates gastric acid secretion which create more acidic environment that can inactivate certain antibiotics ( 21 , 28 , 49 ). Furthermore, this study has found that patients who experienced adverse effects after using medication were about six-fold at risk of eradication failure compared to those with no adverse effects. This increased risk can be attributed by several facts however poor adherence to the medication regimen may be significant reason for eradication failure among these patients. This finding is supported by several other studies which reported that inconsistent intake of medication can reduce the efficacy of the treatment, allowing H. pylori bacteria to survive and continue infecting the gastric mucosa ( 41 , 47 , 51 , 52 ) Limitation of the study This study could not go further to assess the bacterial factors that influence the eradication failure because it faced limited resources. The study couldn’t establish the resistance of H pylori to first line medications because of limited resources. Conclusion The prevalence of H. pylori among adult patients using low dose aspirin is very high and the eradication success is very low compared to the recommendation of WHO. Non adherence of medications, alcohol consumption, and smoking were independent predictors of H. pylori eradication failure among patients using low dose aspirin. Declarations Acknowledgement The authors would like to thank all of the healthcare providers and patients who participated in this study from both Dodoma regional referral hospital and Benjamin Mkapa hospital outpatient clinic in Dodoma Tanzania. I also Thank Dr Emmanuel Sindato and Dr Baraka Alphonce for their guidance and support Authors’ contributions L.J. conceptualized and designed the study also organized and coordinated the research efforts. E.S. and B.A provided guidance during proposal writing, data analysis and final report writing. collected the data from medical outpatient clinic. E.S and B.A were the major contributors in writing the manuscript. All authors reviewed the manuscript. The final manuscript was read and approved by all authors. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors Availability of data and materials Data available on request from the corresponding author. Ethics approval and consent to participate This study was approved by the the University of Dodoma Directorate of Research and Publication (reference number MA.) and was performed in accordance with the principles of the Declaration of Helsinki. All patients provided a written informed consent. In the case of illiterate patients, the consent was read to them in the presence of a literate relative and they provided a fingerprint on the consent form to indicate their informed consent to participate. To those who could not consent due to the severity of their illness, consent was obtained from next of kin who was taking care of the patient. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Author details 1 Department of Internal Medicine, School of medicine and dentistry, the University of Dodoma, Tanzania, 2 Department of Internal Medicine, Dodoma regional referral hospital Tanzania. 3 Department of Internal Medicine, Benjamin Mkapa Hospital Tanzania References Sostres C, Lanas A. Low dose aspirin, H. pylori infection, and the risk of upper gastrointestinal bleeding. Med J Aust. 2018;209(7):297–8. Yoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, et al. Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. Glob Heart. 2024;9(1). Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Reports. 2017;5:183–6. Kristensen AMD, Pareek M, Kragholm KH, Torp-Pedersen C, McEvoy JW, Prescott EB. Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. Eur J Prev Cardiol. 2023;30(12):1172–81. Ansa BE, Hoffman Z, Lewis N, Savoy C, Hickson A, Stone R, et al. Aspirin use among adults with cardiovascular disease in the United States: Implications for an intervention approach. J Clin Med. 2019;8(2):1–13. Tukeni KN, Mohammed EU, Regassa NA, Tukeni BN, Abera EG. The prevalence and correlates of low dose aspirin use for cardiovascular prevention among patients with diabetes mellitus at the Jimma Medical Center, Ethiopia. PAMJ Clin Med. 2023;12. Kim RB, Li A, Park KS, Kang YS, Kim JR, Navarese E, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East Asians With Westerners: A Meta-Analysis. JACC Asia. 2023;3(6):846–62. Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol. 2006 Jun;12(24):3789–92. Zambrana JL, Rodríguez-González FJ, Puente J, Lanas Á, Ferrández Á. Low-dose of aspirin, gastroprotection and Helicobacter pylori erradication (multiple letters) [1]. Rev Esp Cardiol. 2002;55(5):553–4. Furukawa M, Fujita M, Takinishi A, Misaka R, Nagahara H. Low-dose aspirin delays gastric healing after Helicobacter pylori eradication. Intern Med. 2011;50(9):951–9. Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. Curr Probl Cardiol. 2017;42(5):146–64. Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. 2013;19(11):1673–82. Yamamoto T, Mishina Y, Ebato T, Isono A, Abe K, Hattori K. Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. 2010;25:792–4. Hsu P, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des. 2015;21(35):5049–55. Huard K, Haddad K, Saada Y, Nguyen J, Banon D, Matteau A, et al. Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). Sci Rep. 2022;12(1):1–7. Smith SI, Schulz C, Ugiagbe R, Ndip R, Dieye Y, Leja M, et al. Helicobacter pylori Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group. Dig Dis. 2024;42(3):240–56. Nestegard O, Moayeri B, Halvorsen FA, Tønnesen T, Sørbye SW, Paulssen E, et al. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS One. 2022;17(4 April):1–8. Ozeki K, Hada K, Wakiya Y. Factors Influencing the Degree of Gastric Atrophy in Helicobacter pylori Eradication Patients with Drinking Habits. Microorganisms. 2024;12(7):1398. Souissi S, Makni C, Chaieb B, Jarraya A, Toulgui N, Jmal L, et al. Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy. Futur Sci OA. 2024;10(1). Negovan A, Iancu M, Moldovan V, Voidazan S, Bataga S, Pantea M, et al. Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract. 2016;2016. Aumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone RK. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One [Internet]. 2023;18(11 November):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0294403 Fekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S, et al. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23(1):55. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014;20(28):9439–50. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39(1):5–12. Sarri GL, Grigg SE, Yeomans ND. Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. J Gastroenterol Hepatol. 2019;34(3):517–25. Fukuzawa M, Kawai T, Watanabe M, Tomiyama H, Yamashina A, Moriyasu F. Correlation between Helicobacter pylori infection and low-dose aspirin use on damage of the upper gastrointestinal tract. J Gastroenterol Hepatol. 2012;27(SUPPL.3):76–81. Khadim S, Muhammad IN, Alam T, Usman S, Rehman H, Haider S. Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan : A Prospective Exploration of Demographic and Clinical Factors. 2024; Tang Y, Tang G, Pan L, Zhu H, Zhou S, Wei Z. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci Rep [Internet]. 2020;10(1):1–5. Available from: https://doi.org/10.1038/s41598-020-72400-0 Cheng J, Fan C, Li Z, Dong Z, Zhao X, Cai Y, et al. Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clin Exp Gastroenterol. 2024;Volume 17(July):191–200. Baena JM, López C, Hidalgo A, Rams F, Jiménez S, García M, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol. 2002;14(3):291–6. Seo SI, Kang JG, Kim HS, Shin WG, Jang MK, Lee JH, et al. Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection , Nonsteroidal Anti-inflammatory Drugs , and Low-dose Aspirin Therapy in Peptic Ulcer Disease : A Case-control Study. 2019;19(1):42–7. Smith SI, Ajayi A, Jolaiya T, Onyekwere C, Setshedi M, Schulz C, et al. Helicobacter pylori Infection in Africa: Update of the Current Situation and Challenges. Dig Dis. 2022;40(4):535–44. Thorat MA, Cuzick J. Prophylactic use of aspirin : systematic review of harms and approaches to mitigation in the general population Office of National Statistics. 2014; Dumbleton JS, Avery AJ, Coupland C, Hobbs FDR, Kendrick D, Moore M V, et al. EBioMedicine The Helicobacter Eradication Aspirin Trial ( HEAT ): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care. EBIOM. 2015;5–9. Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801–7. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32(7):831–9. Venerito M. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti- inflammatory drugs , antiplatelet agents , anticoagulants , corticosteroids and selective serotonin reuptake inhibitors. 2018;(January):1464–71. Espa C. Low-Dose of Aspirin , Gastroprotection and Helicobacter Pylori Erradication. 2002;55(5):6–7. Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of Helicobacter pylori diagnostic tests: Stool antigen test, urea breath test, rapid urease test, serology and histology. J Res Med Sci. 2011;16(9):1097–104. Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics. 2022;12(2). Lama SD, García DD, Cumplido MT, Álvarez YL. Successful eradication rate of Helicobacter pylori with empirical antibiotic treatment in pediatric patients from a Tertiary Hospital. Andes Pediatr. 2023;94(6):721–8. Peña-Galo E, Gotor J, Harb Y, Alonso M, Alcedo J. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. Gastroenterol Hepatol from Bed to Bench. 2021;14(1):53–8. Shetty V, Lamichhane B, Tay CY, Pai GC, Lingadakai R, Balaraju G, et al. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut Pathog. 2019;11(1):1–8. Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham Y, et al. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. 2020;1–13. Chukwudike ES, Moss SF, Asombang AW. Management of Helicobacter Pylori Infection in Africa : The Challenges and Peculiarities. 2022;Vol. 27(Issue 2):1–9. Butt AMK, Sarwar S, Nadeem MA. Concomitant therapy versus triple therapy: efficacy in H. Pylori eradication and predictors of treatment failure. J Coll Physicians Surg Pakistan. 2021;31(2):128–31. Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: A prospective study. BMC Infect Dis. 2019;19(1):1–7. Zhang L, Eslick GD, Xia HHX, Wu C, Phung N, Talley NJ. Relationship between alcohol consumption and active Helicobacter pylori infection. Alcohol Alcohol. 2009;45(1):89–94. Yu J, Lv Y, Yang P, Jiang Y, Qin X, Wang X. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations. BMC Gastroenterol [Internet]. 2023;23(1):1–13. Available from: https://doi.org/10.1186/s12876-023-03002-z Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard “Maastricht triple therapy.” Aliment Pharmacol Ther. 2001;15(7):1023–9. Gebeyehu E, Nigatu D, Engidawork E. Self-reported adverse drug effects and associated factors among H. Pylori infected patients on standard triple therapy: Prospective follow up study. PLoS One. 2019;14(11):1–15. Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, et al. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Heal. 2021;12. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4950972","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":351478026,"identity":"9b4154cf-eb2f-4f4b-a110-ada410f08545","order_by":0,"name":"Lawi John","email":"","orcid":"","institution":"the University of Dodoma","correspondingAuthor":false,"prefix":"","firstName":"Lawi","middleName":"","lastName":"John","suffix":""},{"id":351478028,"identity":"b9e8d582-c0cd-4d16-84a8-63aebe77b2c8","order_by":1,"name":"Emmanuel Sindato","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA50lEQVRIiWNgGAWjYNACAwbGBgYGxgdAJg8f8VrYGJgNQFrYiLUHpIVNAsQiqIVf7HTixx8Fd2T75zcfq/yaYycDtO3hoxt4tEjOzt0szWPwzHjGMba027LbkoEOYzM2zsHni9u5G6QZDA4nNhzjMbstuY0ZqIWHTRqfFvvbuZt//gBqmQ/UUiy5rZ6wFgPp3G0SPEAtG4BaGD9uO0xYi8Tt3G3WQC3GG4+lJUszbjvOw8ZMwC/8QO/f/PHnsOy8w4cPfvy5rdqen7354WN8WlAAMw+YJFY5CDD+IEX1KBgFo2AUjBgAAFljR994BGnKAAAAAElFTkSuQmCC","orcid":"","institution":"the University of Dodoma","correspondingAuthor":true,"prefix":"","firstName":"Emmanuel","middleName":"","lastName":"Sindato","suffix":""},{"id":351478030,"identity":"351304b1-9fdc-4be5-8a10-85728c6275c1","order_by":2,"name":"Baraka Alphonce","email":"","orcid":"","institution":"the University of Dodoma","correspondingAuthor":false,"prefix":"","firstName":"Baraka","middleName":"","lastName":"Alphonce","suffix":""}],"badges":[],"createdAt":"2024-08-21 10:45:00","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4950972/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4950972/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":67106839,"identity":"3e8d9891-4fd9-4d9d-8960-e1b910461365","added_by":"auto","created_at":"2024-10-21 09:07:33","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":246618,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePatient enrolment\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4950972/v1/0d67035a58842f3c4424cb08.png"},{"id":67106841,"identity":"bb7de2a1-6be1-49c2-a804-99e9988dd074","added_by":"auto","created_at":"2024-10-21 09:07:33","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":110653,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePrevalence of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eHelicobacter pylori\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003eamong low dose aspirin users\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4950972/v1/38278c595e7d45b0984c8803.png"},{"id":67106840,"identity":"13cd5ad0-8cf4-49b8-acfb-ba955d6692ea","added_by":"auto","created_at":"2024-10-21 09:07:33","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":107648,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eH. pylori\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003eeradication rate at Dodoma public hospital\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4950972/v1/11e8d019592a89fa4cff0f7d.png"},{"id":67108923,"identity":"06bead3a-0a68-4ab5-8b64-bf39fbc9980f","added_by":"auto","created_at":"2024-10-21 09:23:37","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1550801,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4950972/v1/97f0f54c-f6d9-423e-910a-1ded8070669a.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003ePrevalence and eradication rate of helicobacter pylori infection among the patient using the low dose of aspirin attending outpatient clinic at tertiary hospitals in Dodoma, Tanzania. A prospective longitudinal observational study\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eGlobally it is estimated that about one billion people are taking a low-dose aspirin(LDA) for both primary prevention and secondary prevention of cardiovascular events(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). The use of low dose aspirin use varies widely across regions with different income groups with lower usage in low- and lower-middle-income countries accounting for 0.6% and 1.2% respectively. The prevalence is much higher in upper-middle-income countries at 11.7% and 17.7% in high-income countries (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIn United states of America (USA) over 30% of adult population are using LDA for primary and secondary prevention of cardiovascular events, however the trend decreased from 32% in 2012 to 30% in 2015 (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). However, the trend of using low dose aspirin is reported to raise significantly in low-income countries because of increased prevalence of cardiovascular disease (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). High prevalence reaching up to 47.2% was reported in sub-Saharan countries (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cem\u003eHelicobacter pylori\u003c/em\u003e infection is very prevalent among patients using low dose aspirin reaching up to 89.8% compared to 68.7% among non-users (Sostres \u0026amp; Lanas, 2018). This higher \u003cem\u003eH. pylori\u003c/em\u003e infection in patients using LDA compared to non-users is a primary result of LDA effect on cyclooxygenase enzymes causing decreased protective prostaglandins in the gastric mucosa (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThis weakened mucosal barrier together with increased gastric acidity due to aspirin creates a favorable environment for \u003cem\u003eH. pylori\u003c/em\u003e colonization and persistence among these patients (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). Damage of gastric mucosal can be caused even with very low doses of aspirin (10 mg daily) because it is known to reduce the levels of gastric mucosal prostaglandins (\u003cspan additionalcitationids=\"CR12 CR13\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSeveral other risk factors for \u003cem\u003eH. pylori\u003c/em\u003e infection in LDA users which are shared with non-users. Such factors include advanced age, concurrent use of corticosteroids or NSAIDs, smoking, alcohol consumption, poor dietary habits, and poor hygiene (\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). These factors tend to compound the mucosal damage resulted from LDA, making the stomach even more susceptible to \u003cem\u003eH. pylori\u003c/em\u003e colonization and persistence (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cem\u003eH. pylori\u003c/em\u003e eradication is potentially significant for preventing complications among LDA users (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). It is necessary to eradicate \u003cem\u003eH. pylori\u003c/em\u003e infection because of its complications including peptic ulcers, gastric cancer, and MALT lymphoma due to chronic inflammation of the stomach lining (\u003cspan additionalcitationids=\"CR19\" citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). The test and treat for H. pylori strategy is reported to be mandatory among patients using LDA especially in settings with high prevalence of \u003cem\u003eH. pylori\u003c/em\u003e (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe eradication rate of \u003cem\u003eH. pylori\u003c/em\u003e infection is termed significant when reaches 90% successful as recommended by WHO (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). the eradication rate of H pylori is still low especially in developing countries where the prevalence is verry high. In Africa the pooled eradication rate was 79% being high in Ethiopia (90%) and lower in East Africa zone including Tanzania (69%) and Kenya (68%), and lowest in Ivory Coast (22.3%) (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eStudies have shown the eradication failure to be higher among LDA users. This is explained mainly by mucosal damage caused by aspirin which creates conducive environment of \u003cem\u003eH. pylori\u003c/em\u003e to persist (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). Also, Aspirin tend to inhibit cyclooxygenase-1 (COX-1) resulting in raised acid production in the stomach hence reducing the effectiveness of some antibiotics like clarithromycin and Amoxicillin (\u003cspan additionalcitationids=\"CR25\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e). Other factors associated with eradication failure includes alcohol consumption, smoking, poor adherence to medication, bacterial resistance, and dosage and timing of dosage (\u003cspan additionalcitationids=\"CR28 CR29\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eUnderstanding the prevalence and eradication rate of \u003cem\u003eH. pylori\u003c/em\u003e among LDA patient population is crucial, as it may shed light on the potential implications of \u003cem\u003eH. pylori\u003c/em\u003e infection on gastrointestinal complications and its association with low dose aspirin use (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e). This study aimed to determine prevalence, eradication rate and risk factors for eradication failure of \u003cem\u003eH. pylori\u003c/em\u003e among patients using LDA attending outpatient clinics at public tertiary hospitals in Dodoma, Tanzania.\u003c/p\u003e"},{"header":"Methodology","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design\u003c/h2\u003e \u003cp\u003eProspective longitudinal observational study\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eStudy settings\u003c/h2\u003e \u003cp\u003eThis study was conducted at two hospitals which are Dodoma regional referral and Benjamin Mkapa hospitals. Dodoma is the capital city of Tanzania with rapidly growing population of 3,085,625 as per national data of 2022 (NBS, 2022). Both hospitals serve as consultancy, diagnostic and teaching hospital of the University of Dodoma. The hospitals offer a wide range of medical specialties including Internal medicine and have equipped laboratories with modern equipment for diagnosis. Benjamin Mkapa hospital and Dodoma regional referral hospital has a bed capacity of 400 and 420 respectively. These hospitals have specialized outpatient clinic of average of aspirin users of 1800 and 2160 at DRRH and BMH respectively per year.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStudy duration\u003c/h2\u003e \u003cp\u003eStudy was conducted for eight (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e) months from September, 2023 to April, 2024.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStudy population\u003c/h2\u003e \u003cp\u003eThe study enrolled adult patients aged 18 years above who are using LDA attending outpatient clinic at department of internal medicine at Dodoma regional referral hospital and Benjamin Mkapa hospital during the study period\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eInclusion criteria\u003c/h2\u003e \u003cp\u003eThe study included adult patients aged 18 years and above using low dose of aspirin\u0026thinsp;\u0026gt;\u0026thinsp;3 months as prophylaxis for MACE, patients voluntarily signed the consent form to participate in the study.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eExclusion Criteria\u003c/h2\u003e \u003cp\u003eAll patients who were using antibiotics within 30 days\u003c/p\u003e \u003cp\u003eAll patients who reported to be allergic to the regimen used in this study\u003c/p\u003e \u003cp\u003eAll patients who were on (PPI, NSAIDS, Macrolides, Bismuth, Steroid, Penicillin\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003esampling technique\u003c/h2\u003e \u003cp\u003eSimple random technique was used to enroll all study participants who met inclusion criteria giving equal chance of participate in this study. Until the sample size was reached.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eSample size estimation\u003c/h2\u003e \u003cp\u003eThe formula (Krejcie \u0026amp;Morgan) was used to calculate sample size as follows:\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$\\:\\text{s}=\\frac{{x}^{2}*N*p\\left(1-p\\right)}{{d}^{2}\\left(N-1\\right)+\\:{\\text{x}}^{2}p\\left(1-p\\right)}$$\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Equb\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equb\" name=\"EquationSource\"\u003e\n$$\\:\\text{s}=\\frac{3.841*3960*0.085\\left(1-0.085\\right)}{{0.05}^{2}\\left(3960-1\\right)+\\:3.841\\text{*}0.085\\left(1-0.085\\right)}$$\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Equc\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equc\" name=\"EquationSource\"\u003e\n$$\\:\\text{s}=\\frac{1182.9857}{10.1627}=116.4046\\:\\approx\\:116\\:\\text{L}\\text{D}\\text{A}\\:\\text{u}\\text{s}\\text{e}\\text{r}\\text{s}.$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eWhere\u003c/b\u003e: \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:p\\)\u003c/span\u003e\u003c/span\u003e = the expected population proportional based on previous studies: 8.5%(\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e)\u003c/p\u003e \u003cp\u003e \u003cspan class=\"InlineEquation\"\u003e \u003cspan class=\"mathinline\"\u003e\\(\\:{x}^{2}\\)\u003c/span\u003e \u003c/span\u003e = the value of chi-square for 1 degree of freedom at 95% confidence level: 3.841.\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e \u003cspan class=\"InlineEquation\"\u003e \u003cspan class=\"mathinline\"\u003e\\(\\:\\:\\:\\:d\\)\u003c/span\u003e \u003c/span\u003e= the degree of accuracy expressed as a proportion: 5%\u003c/p\u003e\u003cp\u003e \u003cspan class=\"InlineEquation\"\u003e \u003cspan class=\"mathinline\"\u003e\\(\\:\\:\\:\\:N\\)\u003c/span\u003e \u003c/span\u003e= the estimated population size of LDA patients served at BMH (1800) and DRRH (2160) per year. \u003cem\u003e(according to BMH and DRRH routine report, 2022).\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003e \u003cspan class=\"InlineEquation\"\u003e \u003cspan class=\"mathinline\"\u003e\\(\\:s\\)\u003c/span\u003e \u003c/span\u003e = required sample size\u003c/p\u003e \u003cp\u003eTherefore, a minimum sample size for this study with an attrition rate of 30% of the sample size calculated was 151 LDA users which were proportionally distributed based on the number of LDA users served annually at BMH and DRRH which is 69 (45.45%) and 82 (54.55%) respectively.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eData collection tools, methods and Procedure\u003c/h2\u003e \u003cdiv id=\"Sec12\" class=\"Section3\"\u003e \u003ch2\u003eData collection tools and methods\u003c/h2\u003e \u003cp\u003eData were collected for the specified period of time by means of face-to-face interview using a structured questionnaire. Data collection was carried out by researcher and research assistant who asked questions to the study participants and explained the meaning of the question so as to ensure uniformity of data. A questionnaire included socio-demographic information, medication use, and factors associated with \u003cem\u003eH. pylori\u003c/em\u003e eradication rates.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStudy procedure\u003c/h2\u003e \u003cp\u003eAll patients using LDA who met inclusion criteria of the study were told the aim, safety and benefits of the study and were requested to sign a written informed consent form. For those who were un able to read and write, researcher or research assistants read for them and they signed form by using thumb sign. History taking, general examination and laboratory investigation commenced after they consent to participate in this study. Prevalence of H. pylori was established by using Stool antigen test as explained below and for those with positive test were then managed by using triple therapy as per STG and then followed up until eighth week post commencement of medication and be tested for H. pylori. All patients with SAT positive at 8 weeks were declared eradication therapy failure, and those with negative SAT were declared eradication therapy success.\u003c/p\u003e \u003cp\u003eDuring follow up phone number of the patients and close relative was used to reach the patients and remind them to come back continuation of treatment regimen and adherence assessment score using MMAS4 and for the stool antigen test. For the patients who did not bring stool sample and those who were not reachable in three consecutive days were considered lost to follow-up. However, in this study there were no lost to follow-up recorded making a response rate of 100% among study participants.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eLaboratory procedure and data collection\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eStool Antigen Testing (SAT)\u003c/strong\u003e \u003cp\u003ethis non-invasive diagnostic method was used for establishing prevalence of H. pylori and assessing eradication rate because it has sensitivity of 95\u0026ndash;100% and specificity of 90%. The test was done first day of enrollment and at eight weeks from day one of treatment for assessing eradication rate. The patient was instructed to collect a small stool sample in a clean, dry, sealable container which was provided at hospital. They were instructed to avoid contamination with urine, water, or toilet paper to ensure clean samples. Stool collection tube must be sterile with built in spoon for collection of specimens, clean dry bed pan or a piece of dry plastic or piece of hard paper Don\u0026rsquo;t urinate on specimen tube container or mix the specimen with water The container was labeled with patients\u0026rsquo; hospital identification number and was sent to laboratory immediately so as can be processed within 72 hours. The stool sample were then tested by immunochromatography assay (H. PYLORI QIUCK CHECK\u0026trade; then laboratory technician assigned for this study and interpretation was sent to researcher for recording.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eFull blood count\u003c/strong\u003e \u003cp\u003ethis was done mainly to assess the hematological parameters with the interest of assessing hemoglobin level and platelets. Blood samples were collected by experienced nurses and doctors who were available at the post during the study period by following all sterile guideline. The EDTA tube with sample was labelled with identification number of the patient and promptly sent to laboratory. The machines. The calibrated XN 2000 SYMEX machine. Made in India. The result was then interpreted by the qualified laboratory technician and then recorded by the researcher.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eDefinition of variables\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eIndependent variables\u003c/strong\u003e \u003cp\u003eIncluded demographic data and clinical characteristics which are, age, gender, place of residence, education level, body mass index. Blood pressure and indication of using low dose of aspirin.\u003c/p\u003e \u003c/p\u003e \u003cp\u003eFactors associated with \u003cem\u003eH. pylori\u003c/em\u003e eradication rates including diagnosed HPI, treatment adherence to medication, medication regimen, symptoms duration, alcoholism, smocking, and chronic medical condition.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eDependent variable\u003c/strong\u003e \u003cp\u003ewas eradication of pylori infection at eighth week post commencement of medication. It was categorized into two groups which were eradication success and eradication failure when test was negative and positive respectively.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eValidity and reliability\u003c/h2\u003e \u003cdiv id=\"Sec17\" class=\"Section3\"\u003e \u003ch2\u003eStudy validity\u003c/h2\u003e \u003cp\u003eBefore gathering data, a comprehensive process was undertaken to ensure the questionnaire validity. Initially, pilot study was done at DRRH including 15 patients to assess the questionnaire's consistency and any potential issues were identified and corrected with aid from supervisors. Additionally, to maintain the quality of data collection, the research assistants were provided with comprehensive training and orientation by the principal researcher. This training equipped them with the necessary skills and knowledge to proficiently carry out their duties and responsibilities in the research process, ensuring the validity of the data collected for the study\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eReliability\u003c/h2\u003e \u003cp\u003e All laboratory procedures were conducted by the experienced laboratory technicians designated for the study under the standard guideline adapted by both hospitals. Also, all blood sample were collected by well experienced doctors and nurses by following the standard protocols.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eData analysis\u003c/h2\u003e \u003cp\u003eData was analyzed by using IBM SPSS version 26. Descriptive statistics were used to summarize demographic and clinical characteristics. All categorical variables were analyzed as frequency and percentages whereas continuous variables were analyzed as mean with standard deviation or medians with interquartile ranges according to distribution of data.\u003c/p\u003e \u003cp\u003eInferential statistics included the use of Pearson\u0026rsquo;s chi-square test and binary logistic regression to assess association between independent and dependent variables. This was done to assess factors associated with eradication rate of H. pylori in such a way that; all variables with p value less than 0.2 in chi square test were taken into univariate regression where crude odds ratio was established. All variables with p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was then subjected into multivariable regression where adjusted odds ratio was established after controlling cofounders. 95% confidence interval was calculated and a p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were considered statistically significant.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eEthical consideration\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eEthical approval\u003c/strong\u003e \u003cp\u003ewas obtained from the University of Dodoma\u0026rsquo;s IRREC with reference letter number MA.84/261/02/A/66/9. Letter was submitted to hospital directors of BMH and DRRH for data collection permit. Permit was released from both health facility and data collection exercise effectively started from October 2023.\u003c/p\u003e \u003c/p\u003e \u003cp\u003eStringent measures were implemented to safeguard the confidentiality of participants and protect their sensitive information throughout the study. To maintain anonymity, participants were assigned unique identification numbers rather than using their real names. All study-related documents, both hard copies and electronic files, were stored in a highly secure location, accessible only to authorized personnel, including the principal investigator and research assistants. Electronic data were further fortified through the use of robust password protection. The utmost care was taken to ensure that all information collected from participants remained strictly confidential.\u003c/p\u003e \u003cp\u003eThe participants were informed that they had a chance to withdraw from the study at any stage of the study, and were given an equal care with those who have remained in the study. Participants tested positive kept on regimen of Triple therapy for 2 weeks then follow up after 8 weeks those still tested positive declared as eradication failure and referred on second line regime as per protocol suggested HDDT or Bismuth quadruple therapy. Close follow up are done for eradication of helicobacter pylori infection.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec22\"\u003e\n \u003ch2\u003eStudy participant enrolment flow Chart\u003c/h2\u003e\n \u003cdiv id=\"Sec23\"\u003e\n \u003ch2\u003eSocio-Demographic and Clinical Characteristics of Study Participants\u003c/h2\u003e\n \u003cp\u003eThe total number of patients using low dose of aspirin attended from both tertiary hospitals were 1321 in which 981 were excluded due to antibiotic use. 341 patients met inclusion criteria in which 181 patients were excluded due to sampling technique. Therefore, total number of participants enrolled in this study were 159, with median age of study participants was 59 years (IQR 20\u0026ndash;75 years) majority were aged 60 years and above 75(49.7%) followed by 40\u0026ndash;59 years (48.31.8%). Female gender was the most encountered among these patients accounting 87(57.7%), regarding education level majority accounting 56(37.1%) had secondary education followed by college level (Table.1).\u003c/p\u003e\n \u003cp\u003eMajority of study participants had elevated blood pressure, about 48(31.8%) were using alcohol, total of 34 (22.5%) were smoking whereby 19(55.9%) were smoking less than 20 packs per year and 15(44.1%) were smoking more than 20 packs per year. Significant number of these patients had anemia with Hemoglobin less than 11.5g/dl, they were about 31(20.5%) (Table\u0026nbsp;4.1).\u003c/p\u003e\n \u003cp\u003eRegarding medical history of patients using low dose aspirin, majority were under this medication for more than 12 months followed by 7\u0026ndash;12 months accounting 60(39.7) and 50(33.1%) respectively. The most common medical condition which was the reason of using low dose aspirin were ischemic heart disease 50(33.3%), myocardial infarction 32(21.2%) and stroke 24(15.9%) (Table\u0026nbsp;4.2).\u003c/p\u003e\n \u003cdiv\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv\u003eTable 1\u003c/div\u003e\n \u003cdiv\u003e\n \u003cp\u003eSocio-demographics and clinical characteristics of patients using low dose aspirin (N\u0026thinsp;=\u0026thinsp;151)\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eVariables\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eFrequency (n)\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e59.0\u0026thinsp;\u0026plusmn;\u0026thinsp;20 \u003cstrong\u003eMedian (IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAge group (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt; 40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e18.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40\u0026ndash;59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e31.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026ge; 60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e49.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e64\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e42.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e87\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e57.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eEducation level\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNon formal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePrimary\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e21.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSecondary\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e37.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCollege\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBody mass index(kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNormal (18.5\u0026ndash;25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e29.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eOver weight (25-29.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e58.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eObese (\u0026ge;\u0026thinsp;30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e11.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBlood pressure (mm hg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNormal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e22.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eElevated\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eStage one\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e30.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eStage two\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e13.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAlcohol use\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e31.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e103\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e68.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSmoking\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e22.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e117\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e77.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSource of water\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBoiled water\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e110\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e72.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eUn boiled water\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e27.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHemoglobin level (g/dl)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026lt;11.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026ge;11.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e120\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e79.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eDuration of LDA 75mg\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e3\u0026ndash;6 months\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e27.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e7\u0026ndash;12 months\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u0026gt;12 months\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e39.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003eTherapy used\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003elansoprazole 20mg\u0026thinsp;+\u0026thinsp;Clarithromycin 500\u0026thinsp;+\u0026thinsp;Tinidazole 500mg BID 14/7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e38.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRabeprazole 20mg\u0026thinsp;+\u0026thinsp;amoxicillin 1000mg 12hrly for 14/7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e35.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNegative Stool for antigen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e25.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003eIndication of LDA\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIschemic heart disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e87\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e57.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eStroke\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e24.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePeripheral arterial disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e17.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n \u003cp\u003e\u003cstrong\u003ePrevalence of H. Pylori Infection among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe prevalence of helicobacter pylori among patients using low dose aspirin was noted to be unacceptably very high reaching 74.8% (Fig.\u0026nbsp;4.1). Helicobacter pylori was diagnosed by using stool antigen test.\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eHelicobacter Pylori\u003c/strong\u003e \u003cstrong\u003eEradication Rate among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eTotal of 81(71.7%) patients using low dose aspirin were tested negative at eight weeks. The eradication rate of \u003cem\u003eH. pylori\u003c/em\u003e among patients using low dose Aspirin was as high as 71.7% where ass eradication failure was reaching up to 28.3% (Fig. 4.2).\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eFactors Associated with Eradication Failure of H. Pylori Infection among Low Dose Aspirin Users Attending Clinics at Public Hospitals in Dodoma\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eIn chi square test several factors were found to be associated with eradication failure of helicobacter pylori. Such factors are Age (p value\u0026thinsp;=\u0026thinsp;0.037), use of alcohol (p value\u0026thinsp;=\u0026thinsp;0.006), smoking (p value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and self-reported adverse effect of medication (p value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Table\u0026nbsp;4.3). All variables showing significant association with p value less than 0.05 were taken into univariate regression along with those with p value less than 0.025.\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eTable\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e3\u003c/strong\u003e\u003cstrong\u003e: Univariate and multivariate regression of factors associated with helicobacter pylori eradication failure\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cdiv align=\"center\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eH. pylori eradication\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eUnivariate regression\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMultivariable regression\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSuccess (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eFailure (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOR (95% CI)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eAOR (95% CI)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026lt;40\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e11(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e11(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3.0(1.07-8.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.037\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.20(0.04-1.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;40- 59 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e28(80.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7(20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.8(0.27-2.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.582\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.24(0.05-1.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.079\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026ge;60 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e42(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e14(25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eSex\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Male\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e31(66.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e16(34.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e50(75.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e16(24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1.6(0.71-3.68)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.256\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eBody mass index (BMI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Normal (18.5-25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e28(77.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8(22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Overweight (25-29.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e46(74.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e16(25.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1.22(0.46-3.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.691\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.55(0.62-1.86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.332\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Obese (\u0026gt;30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4.0(1.11-14.43)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.034\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5.44(0.85-34.79)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e0.074\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eAlcohol use\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e21(55.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e17(44.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3.24(1.38-7.61)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e3.70(1.07-12,80)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.039\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e60(80.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e15(20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSmoking\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8(33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e16(66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e9.13(3.34-24.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e8.16(1.31-50.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.025\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e73(82.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e16(18.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eNon adherence to treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e10(41.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e14(58.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5.5(2.11-14.46)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5.6(1.60-19.31)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e71(79.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e18(20.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n \u003cp\u003eIn univariate binary regression, several variables were statistically significantly associated with h. pylori eradication failure. Such variables include age below 40 years [p value\u0026thinsp;=\u0026thinsp;0.037, COR\u0026thinsp;=\u0026thinsp;3.0, 95% CI (1.07\u0026ndash;8.42)], obesity [p value\u0026thinsp;=\u0026thinsp;0.034, COR\u0026thinsp;=\u0026thinsp;4.0, 95% CI (1.11\u0026ndash;14.43)], use of alcohol [p value\u0026thinsp;=\u0026thinsp;0.007, COR\u0026thinsp;=\u0026thinsp;3.24, 95% CI (1.38\u0026ndash;7.61)]. Other variables were non adherence of medication due to self-reported adverse effect [p value\u0026thinsp;=\u0026thinsp;0.001, COR\u0026thinsp;=\u0026thinsp;5.5, 95% CI (2.11\u0026ndash;14.46)], smoking [p value\u0026thinsp;\u0026lt;\u0026thinsp;0.001, COR\u0026thinsp;=\u0026thinsp;9.13, 95% CI (3.34\u0026ndash;24.97)] (Table\u0026nbsp;4.4). All variables with p value less than 0.05 in univariate were then taken into multivariate regression to establish adjusted odds ratio.\u003c/p\u003e\n \u003cp\u003eIn multivariate regression, it was found that patients with non- adherence to medication were about six-fold at risk of eradication failure compared to their counterpart [p value 0.007, AOR\u0026thinsp;=\u0026thinsp;5.6, 95% CI (1.6-19.31)]. Also, patients with history of using alcohol were approximately four times at high risk of eradication failure compared to those who do not use alcohol. Furthermore, smoking was significant factor for eradication failure in such a way that patients who are smoking were eight-fold at risk of eradication failure compared to those who do not smoke at all [p value\u0026thinsp;=\u0026thinsp;0.025, AOR\u0026thinsp;=\u0026thinsp;8.16, 95% CI (1.31\u0026ndash;50.94) (Table 4.4).\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eTable\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e4\u003c/strong\u003e\u003cstrong\u003e: Univariate and multivariate regression of factors associated with helicobacter pylori eradication failure\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cdiv align=\"center\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 22%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eH. pylori eradication\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 25%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eUnivariate regression\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 28%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMultivariable regression\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSuccess (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFailure (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCOR (95% CI)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAOR (95% CI)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026lt;40\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e11(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e11(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e3.0(1.07-8.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.037\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e0.20(0.04-1.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;40- 59 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e28(80.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e7(20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e0.8(0.27-2.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e0.582\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e0.24(0.05-1.18)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e0.079\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026ge;60 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e42(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e14(25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003eSex\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Male\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e31(66.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e16(34.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e50(75.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e16(24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e1.6(0.71-3.68)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e0.256\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003eBody mass index (BMI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Normal (18.5-25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e28(77.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e8(22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Overweight (25-29.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e46(74.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e16(25.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e1.22(0.46-3.21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e0.691\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e0.55(0.62-1.86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e0.332\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Obese (\u0026gt;30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e7(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e8(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e4.0(1.11-14.43)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.034\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e5.44(0.85-34.79)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e0.074\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003eAlcohol use\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e21(55.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e17(44.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e3.24(1.38-7.61)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e3.70(1.07-12,80)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.039\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e60(80.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e15(20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSmoking\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e8(33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e16(66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e9.13(3.34-24.97)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e8.16(1.31-50.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.025\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e73(82.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e16(18.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eNon adherence to treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e10(41.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e14(58.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003e5.5(2.11-14.46)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e5.6(1.60-19.31)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 23%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11%;\"\u003e\n \u003cp\u003e71(79.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e18(20.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17%;\"\u003e\n \u003cp\u003eRef\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 8%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\u0026nbsp;\n \u003c/div\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe prevalence of helicobacter pylori among patients using low dose aspirin in this study was noted to be very high accounting for 74.8%. The prevalence of \u003cem\u003eH. pylori\u003c/em\u003e infection among patients using low dose aspirin is reported to be high in different geographical locations, however many studies reported the prevalence to be very high in developing countries (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e). Several other studies have reported that \u003cem\u003e\"H. pylori\u003c/em\u003e infection is frequently found in LDA users. A systematic review and meta-analysis which involved new studies from different regions including Europe, Japan and Asia reported the increased \u003cem\u003eH. pylori\u003c/em\u003e complication among the LDA users (\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cem\u003eH. pylori\u003c/em\u003e prevalence is reported to be 50% of the global population, varying from 20\u0026ndash;40% in developed nations and more than 80% in certain developing countries which is very similar to this study. However, the study done in UK was contrary to other studies in same developed countries and was similar to our study with very high prevalence reaching up to 89.8% among LDA users and 68.7% among non-users. (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). However, this systematic review was different from a reported randomized trial which included studies done in United Kingdom (UK), Wales and Northern Ireland where the prevalence 17% (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e). However, in this study serological test was used to establish the prevalence which was different from other study which used SAT. The study findings in this region shows that the low prevalence and eradication rate was observed to be higher than in places with high prevalence. Among low dose aspirin users. Furthermore the study reported that in the pilot study the prevalence found to be 23% with eradication success of 91.3%.eradication success was confirmed by using breath test (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSome cohort studies conducted in Korea have reported the composite prevalence of \u003cem\u003eH. pylori\u003c/em\u003e among patients using Low dose aspirin presenting with Upper Gastrointestinal Bleeding (UGIB) to be 64.2%. The research revealed that among the individuals examined, 57.9% in the study group and 51.8% in the control group were identified as having \u003cem\u003eH. pylori\u003c/em\u003e infection. The diagnostic test used was Urease test which is different from our study (\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe prevalence of H. pylori among LDA users can be explained based on various facts. Such facts include the direct mucosal damage caused by aspirin which expose the gastric mucosal leading to invasion of H pylori. Low-dose aspirin inhibit cyclooxygenase (COX) enzymes which reduce the protective prostaglandins hence increasing the vulnerability to H. pylori invasion. Some studies reported the synergism oh H. pylori and LDA in such a way that H. pylori tend to induces chronic inflammation in the gastric mucosa and adheres to damaged area which exacerbating the mucosal damage caused by Aspirin (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan additionalcitationids=\"CR37\" citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003eHelicobacter Pylori Eradication Rate among Low Dose Aspirin Users\u003c/h2\u003e \u003cp\u003eIn this study eradication of H. pylori was assessed by using the stool antigen test (SAT) at eighth week post treatment commencement. This non-invasive diagnostic test is well reliable because it has high sensitivity ranging from 90\u0026ndash;95% and specificity ranging from 95\u0026ndash;98%, meaning that the test has a high accuracy in correctly identifying those with and without the infection respectively (\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e). In this study the eradication success of H. pylori was 71.7% among patients using low dose aspirin at eight weeks. The eradication failure of \u003cem\u003eH. pylori\u003c/em\u003e was reaching up to 28.3%. According to Khadim et al. (2024) and other scholars the effectiveness of H. pylori eradication is classified as excellent if the success rate is 95% or higher, good if it is 90% or higher, borderline acceptable if it falls between 85% and 89%, and unacceptable if it is below 85% (\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e). The eradication rate observed in this study was under the category of unacceptable eradication success which accounted for 71.7%.\u003c/p\u003e \u003cp\u003eSimilar to this study, several studies have reported \u003cem\u003eH. pylori\u003c/em\u003e eradication success rates below 90% which is recommended by WHO. A systematic analysis of 22 studies in Africa have revealed a pooled eradication rate of 79%. This systematic analysis reported significant variability, with higher success rate in Ethiopia (90%), Nigeria (87%), South Africa (86%), Egypt (82%), and Morocco (82%). However, lower rates were reported most in East Africa zone including in Tanzania (69%) and Kenya (68%), while the lowest being in Ivory Coast (22.3%) (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). This lower rate were also observed in Chile where eradication rate was reported to be 38% (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e). The challenge of eradicating H. Pylori is higher even in some developed countries including Spain where it was reported to be 71.1% which is lower than the recommended by WHO (\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe observed lower eradication rates of H. pylori infection may be explained by several factors varying from antibiotic resistance where H. pylori strains can be resistant to key medication like clarithromycin and metronidazole and amoxicillin. Some studies have reported the resistance reaching up to 90% to metronidazole which is used in many of the eradication therapy in Africa including Tanzania (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e). Also, inadequate treatment regimens which is explained by suboptimal dosages and treatment duration (\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e) poor patient adherence to medication, and poor healthcare system are significant challenges mainly in developing countries (\u003cspan additionalcitationids=\"CR46\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eEradication success of H. pylori is very low and vary with region being higher in sub-Saharan Africa including the east Africa zone. This variability may be suggestive of resistivity of bacteria due to several factors including over the counter drugs which exposes patients to antibiotic resistance. Regarding that the sensitivity test for H. pylori is costly and hard to be managed by each hospital, the regional test may be useful in establishing the effective regimen so as to raise the eradication rate of H. pylori among patients.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003ePredictors of Eradication failure of H. pylori\u003c/h2\u003e \u003cp\u003eThis study has found significant predictors of H. pylori eradication failure include the use of alcohol, smoking, and self-reported adverse effect of medication. Similar findings were reported from other studies including that of China which showed that excessive alcohol consumption and smoking were independent predictors of H. pylori eradication failure (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e), however another study done in China have reported association between alcohol and smoking with eradication failure in \u0026gt;\u0026thinsp;7 days regimen but no significant association when vonoprazan (VPZ)-based therapy regimen was given (\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e). The difference in regimen may be the great influence on eradication failure as studies have shown H. pylori have developed resistance to most of used antibiotics. However, there may also be some effect of alcohol on non VPZ based regime.\u003c/p\u003e \u003cp\u003eAlcohol consumption can negatively impact the eradication of H. pylori by several mechanisms. Alcohol may cause direct irritation and inflammation of the gastric mucosa which hinder the healing process and reduce the effectiveness of antibiotic therapy (\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e).Furthermore, alcohol tend to interfere with the metabolism and absorption of the medications used to eradicate H. pylori hence reducing their concentration in the stomach which lead to eradication failure (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSmoking is a significant factor for eradication failure, this may be because smoking cause detrimental effects on gastric health and H. pylori eradication. Smoking reduces gastric blood flow, which can impair the delivery of antibiotics to the stomach lining (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). Also, smoking stimulates gastric acid secretion which create more acidic environment that can inactivate certain antibiotics (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eFurthermore, this study has found that patients who experienced adverse effects after using medication were about six-fold at risk of eradication failure compared to those with no adverse effects. This increased risk can be attributed by several facts however poor adherence to the medication regimen may be significant reason for eradication failure among these patients. This finding is supported by several other studies which reported that inconsistent intake of medication can reduce the efficacy of the treatment, allowing H. pylori bacteria to survive and continue infecting the gastric mucosa (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e, \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section2\"\u003e \u003ch2\u003eLimitation of the study\u003c/h2\u003e \u003cp\u003eThis study could not go further to assess the bacterial factors that influence the eradication failure because it faced limited resources. The study couldn\u0026rsquo;t establish the resistance of H pylori to first line medications because of limited resources.\u003c/p\u003e \u003c/div\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe prevalence of H. pylori among adult patients using low dose aspirin is very high and the eradication success is very low compared to the recommendation of WHO.\u003c/p\u003e \u003cp\u003eNon adherence of medications, alcohol consumption, and smoking were independent predictors of H. pylori eradication failure among patients using low dose aspirin.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgement\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors would like to thank all of the healthcare providers and patients who participated in this study from both Dodoma regional referral hospital and Benjamin Mkapa hospital outpatient clinic in Dodoma Tanzania. I also Thank Dr Emmanuel Sindato and Dr Baraka Alphonce for their guidance and support\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eL.J. \u0026nbsp; conceptualized and designed the study also organized and coordinated the research efforts. E.S. and B.A provided guidance during proposal writing, data analysis and final report writing. collected the data from medical outpatient clinic. E.S and B.A were the major contributors in writing the manuscript. All authors reviewed the manuscript. The final manuscript was read and approved by all authors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData available on request from the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;This study was approved by the the University of Dodoma Directorate of Research and Publication (reference number MA.) and was performed in accordance with the principles of the Declaration of Helsinki. All patients provided a written informed consent. In the case of illiterate patients, the consent was read to them in the presence of a literate relative and they provided a fingerprint on the consent form to indicate their informed consent to participate. To those who could not consent due to the severity of their illness, consent was obtained from next of kin who was taking care of the patient.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Consent for publication\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor details\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp; 1\u003c/sup\u003eDepartment of Internal Medicine, School of medicine and dentistry, the University of Dodoma, Tanzania, \u003csup\u003e2\u003c/sup\u003eDepartment of Internal Medicine, Dodoma regional referral hospital Tanzania. \u003csup\u003e3\u003c/sup\u003eDepartment of Internal Medicine, Benjamin Mkapa Hospital Tanzania\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eSostres C, Lanas A. Low dose aspirin, H. pylori infection, and the risk of upper gastrointestinal bleeding. Med J Aust. 2018;209(7):297\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eYoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, et al. Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. Glob Heart. 2024;9(1). \u003c/li\u003e\n\u003cli\u003eStuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012\u0026ndash;2015. Prev Med Reports. 2017;5:183\u0026ndash;6. \u003c/li\u003e\n\u003cli\u003eKristensen AMD, Pareek M, Kragholm KH, Torp-Pedersen C, McEvoy JW, Prescott EB. Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. Eur J Prev Cardiol. 2023;30(12):1172\u0026ndash;81. \u003c/li\u003e\n\u003cli\u003eAnsa BE, Hoffman Z, Lewis N, Savoy C, Hickson A, Stone R, et al. Aspirin use among adults with cardiovascular disease in the United States: Implications for an intervention approach. J Clin Med. 2019;8(2):1\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eTukeni KN, Mohammed EU, Regassa NA, Tukeni BN, Abera EG. The prevalence and correlates of low dose aspirin use for cardiovascular prevention among patients with diabetes mellitus at the Jimma Medical Center, Ethiopia. PAMJ Clin Med. 2023;12. \u003c/li\u003e\n\u003cli\u003eKim RB, Li A, Park KS, Kang YS, Kim JR, Navarese E, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East Asians With Westerners: A Meta-Analysis. JACC Asia. 2023;3(6):846\u0026ndash;62. \u003c/li\u003e\n\u003cli\u003eJi KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol. 2006 Jun;12(24):3789\u0026ndash;92. \u003c/li\u003e\n\u003cli\u003eZambrana JL, Rodr\u0026iacute;guez-Gonz\u0026aacute;lez FJ, Puente J, Lanas \u0026Aacute;, Ferr\u0026aacute;ndez \u0026Aacute;. Low-dose of aspirin, gastroprotection and Helicobacter pylori erradication (multiple letters) [1]. Rev Esp Cardiol. 2002;55(5):553\u0026ndash;4. \u003c/li\u003e\n\u003cli\u003eFurukawa M, Fujita M, Takinishi A, Misaka R, Nagahara H. Low-dose aspirin delays gastric healing after Helicobacter pylori eradication. Intern Med. 2011;50(9):951\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eLavie CJ, Howden CW, Scheiman J, Tursi J. Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. Curr Probl Cardiol. 2017;42(5):146\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eIwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. 2013;19(11):1673\u0026ndash;82. \u003c/li\u003e\n\u003cli\u003eYamamoto T, Mishina Y, Ebato T, Isono A, Abe K, Hattori K. Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. 2010;25:792\u0026ndash;4. \u003c/li\u003e\n\u003cli\u003eHsu P, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des. 2015;21(35):5049\u0026ndash;55. \u003c/li\u003e\n\u003cli\u003eHuard K, Haddad K, Saada Y, Nguyen J, Banon D, Matteau A, et al. Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). Sci Rep. 2022;12(1):1\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eSmith SI, Schulz C, Ugiagbe R, Ndip R, Dieye Y, Leja M, et al. Helicobacter pylori Diagnosis and Treatment in Africa: The First Lagos Consensus Statement of the African Helicobacter and Microbiota Study Group. Dig Dis. 2024;42(3):240\u0026ndash;56. \u003c/li\u003e\n\u003cli\u003eNestegard O, Moayeri B, Halvorsen FA, T\u0026oslash;nnesen T, S\u0026oslash;rbye SW, Paulssen E, et al. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS One. 2022;17(4 April):1\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eOzeki K, Hada K, Wakiya Y. Factors Influencing the Degree of Gastric Atrophy in Helicobacter pylori Eradication Patients with Drinking Habits. Microorganisms. 2024;12(7):1398. \u003c/li\u003e\n\u003cli\u003eSouissi S, Makni C, Chaieb B, Jarraya A, Toulgui N, Jmal L, et al. Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy. Futur Sci OA. 2024;10(1). \u003c/li\u003e\n\u003cli\u003eNegovan A, Iancu M, Moldovan V, Voidazan S, Bataga S, Pantea M, et al. Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract. 2016;2016. \u003c/li\u003e\n\u003cli\u003eAumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone RK. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One [Internet]. 2023;18(11 November):1\u0026ndash;13. Available from: http://dx.doi.org/10.1371/journal.pone.0294403\u003c/li\u003e\n\u003cli\u003eFekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S, et al. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23(1):55. \u003c/li\u003e\n\u003cli\u003eSostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014;20(28):9439\u0026ndash;50. \u003c/li\u003e\n\u003cli\u003eErah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39(1):5\u0026ndash;12. \u003c/li\u003e\n\u003cli\u003eSarri GL, Grigg SE, Yeomans ND. Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. J Gastroenterol Hepatol. 2019;34(3):517\u0026ndash;25. \u003c/li\u003e\n\u003cli\u003eFukuzawa M, Kawai T, Watanabe M, Tomiyama H, Yamashina A, Moriyasu F. Correlation between Helicobacter pylori infection and low-dose aspirin use on damage of the upper gastrointestinal tract. J Gastroenterol Hepatol. 2012;27(SUPPL.3):76\u0026ndash;81. \u003c/li\u003e\n\u003cli\u003eKhadim S, Muhammad IN, Alam T, Usman S, Rehman H, Haider S. Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan : A Prospective Exploration of Demographic and Clinical Factors. 2024; \u003c/li\u003e\n\u003cli\u003eTang Y, Tang G, Pan L, Zhu H, Zhou S, Wei Z. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci Rep [Internet]. 2020;10(1):1\u0026ndash;5. Available from: https://doi.org/10.1038/s41598-020-72400-0\u003c/li\u003e\n\u003cli\u003eCheng J, Fan C, Li Z, Dong Z, Zhao X, Cai Y, et al. Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clin Exp Gastroenterol. 2024;Volume 17(July):191\u0026ndash;200. \u003c/li\u003e\n\u003cli\u003eBaena JM, L\u0026oacute;pez C, Hidalgo A, Rams F, Jim\u0026eacute;nez S, Garc\u0026iacute;a M, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol. 2002;14(3):291\u0026ndash;6. \u003c/li\u003e\n\u003cli\u003eSeo SI, Kang JG, Kim HS, Shin WG, Jang MK, Lee JH, et al. Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection , Nonsteroidal Anti-inflammatory Drugs , and Low-dose Aspirin Therapy in Peptic Ulcer Disease : A Case-control Study. 2019;19(1):42\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eSmith SI, Ajayi A, Jolaiya T, Onyekwere C, Setshedi M, Schulz C, et al. Helicobacter pylori Infection in Africa: Update of the Current Situation and Challenges. Dig Dis. 2022;40(4):535\u0026ndash;44. \u003c/li\u003e\n\u003cli\u003eThorat MA, Cuzick J. Prophylactic use of aspirin : systematic review of harms and approaches to mitigation in the general population Office of National Statistics. 2014; \u003c/li\u003e\n\u003cli\u003eDumbleton JS, Avery AJ, Coupland C, Hobbs FDR, Kendrick D, Moore M V, et al. EBioMedicine The Helicobacter Eradication Aspirin Trial ( HEAT ): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care. EBIOM. 2015;5\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eKim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eFletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32(7):831\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eVenerito M. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti- inflammatory drugs , antiplatelet agents , anticoagulants , corticosteroids and selective serotonin reuptake inhibitors. 2018;(January):1464\u0026ndash;71. \u003c/li\u003e\n\u003cli\u003eEspa C. Low-Dose of Aspirin , Gastroprotection and Helicobacter Pylori Erradication. 2002;55(5):6\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eKazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of Helicobacter pylori diagnostic tests: Stool antigen test, urea breath test, rapid urease test, serology and histology. J Res Med Sci. 2011;16(9):1097\u0026ndash;104. \u003c/li\u003e\n\u003cli\u003eCardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics. 2022;12(2). \u003c/li\u003e\n\u003cli\u003eLama SD, Garc\u0026iacute;a DD, Cumplido MT, \u0026Aacute;lvarez YL. Successful eradication rate of Helicobacter pylori with empirical antibiotic treatment in pediatric patients from a Tertiary Hospital. Andes Pediatr. 2023;94(6):721\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003ePe\u0026ntilde;a-Galo E, Gotor J, Harb Y, Alonso M, Alcedo J. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. Gastroenterol Hepatol from Bed to Bench. 2021;14(1):53\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eShetty V, Lamichhane B, Tay CY, Pai GC, Lingadakai R, Balaraju G, et al. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut Pathog. 2019;11(1):1\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eLuo L, Ji Y, Yu L, Huang Y, Liang X, Graham Y, et al. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. 2020;1\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eChukwudike ES, Moss SF, Asombang AW. Management of Helicobacter Pylori Infection in Africa : The Challenges and Peculiarities. 2022;Vol. 27(Issue 2):1\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eButt AMK, Sarwar S, Nadeem MA. Concomitant therapy versus triple therapy: efficacy in H. Pylori eradication and predictors of treatment failure. J Coll Physicians Surg Pakistan. 2021;31(2):128\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eJaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: A prospective study. BMC Infect Dis. 2019;19(1):1\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eZhang L, Eslick GD, Xia HHX, Wu C, Phung N, Talley NJ. Relationship between alcohol consumption and active Helicobacter pylori infection. Alcohol Alcohol. 2009;45(1):89\u0026ndash;94. \u003c/li\u003e\n\u003cli\u003eYu J, Lv Y, Yang P, Jiang Y, Qin X, Wang X. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations. BMC Gastroenterol [Internet]. 2023;23(1):1\u0026ndash;13. Available from: https://doi.org/10.1186/s12876-023-03002-z\u003c/li\u003e\n\u003cli\u003ePerri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard \u0026ldquo;Maastricht triple therapy.\u0026rdquo; Aliment Pharmacol Ther. 2001;15(7):1023\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eGebeyehu E, Nigatu D, Engidawork E. Self-reported adverse drug effects and associated factors among H. Pylori infected patients on standard triple therapy: Prospective follow up study. PLoS One. 2019;14(11):1\u0026ndash;15. \u003c/li\u003e\n\u003cli\u003eCort\u0026eacute;s P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, et al. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Heal. 2021;12. \u003cstrong\u003e\u003cstrong\u003e\u003cstrong\u003e\u003cstrong\u003e\u003c/strong\u003e\u003c/strong\u003e\u003c/strong\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Helicobacter pylori infection, low dose of aspirin, eradication rate, risk factors","lastPublishedDoi":"10.21203/rs.3.rs-4950972/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4950972/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eIntroduction:\u003c/h2\u003e \u003cp\u003eLow-dose of aspirin has been widely used by health providers as primary prevention of major cardiovascular events, its benefit counterbalanced by side effects The synergistic interaction between \u003cem\u003eH. pylori\u003c/em\u003e infection and LDA use has been identified as a significant risk factor for peptic ulcer disease, chronic gastritis, perforation, bleeding and gastric cancer with increase folds two to three times among \u003cem\u003eH\u003c/em\u003e. pylori positive patient.\u003c/p\u003e\u003ch2\u003eMethodology:\u003c/h2\u003e \u003cp\u003e A prospective observational longitudinal study was carried out for patients using the low dose of aspirin attended outpatient clinic at Benjamin Mkapa Hospital and Dodoma Regional Referral Hospital in between September, 2023 to April, 2024.A sample size of 159 participants were recruited, aged 18 years or older met specified inclusion criteria. At baseline Demographic data, clinical characteristics were extracted from questionnaire form. Blood sample was collected for full blood picture and stool for \u003cem\u003eH. pylori\u003c/em\u003e antigen test. Data analysis employing frequencies, chi-square test and binary logistic regression was done by using SPSS version 26. Statistical significance was ruled out for \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAmong 159 patients enrolled in this study, mean age was 57 (IQR 20\u0026ndash;75), 57.7% were female. The prevalence was 74.8%. Variables which show significance in this study include use of alcohol [p value\u0026thinsp;=\u0026thinsp;0.007, OR\u0026thinsp;=\u0026thinsp;3.24, 95% CI (1.38\u0026ndash;7.61)], non-adherence of medications [p value\u0026thinsp;=\u0026thinsp;0.001, OR\u0026thinsp;=\u0026thinsp;5.5, 95% CI (2.11\u0026ndash;14.46)], smoking [p value\u0026thinsp;\u0026lt;\u0026thinsp;0.001, OR\u0026thinsp;=\u0026thinsp;13.61, 95% CI (2.30\u0026ndash;56.30)].\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003e \u003cem\u003eH\u003c/em\u003e. pylori infection is frequently observed in patients using low dose of aspirin attending medical clinic to tertiary hospital in Dodoma. Factors which have significance with helicobacter pylori eradication failure were smoking, alcohol and non-adherence to medication during treatment period.\u003c/p\u003e","manuscriptTitle":"Prevalence and eradication rate of helicobacter pylori infection among the patient using the low dose of aspirin attending outpatient clinic at tertiary hospitals in Dodoma, Tanzania. A prospective longitudinal observational study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-21 09:07:28","doi":"10.21203/rs.3.rs-4950972/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"cffe6994-3d87-47ac-97cb-a573b63065f1","owner":[],"postedDate":"October 21st, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-10-21T09:07:30+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-21 09:07:28","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4950972","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4950972","identity":"rs-4950972","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}